Business Description
Shedir Pharma Group SpA
ISIN : IT0005379620
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.33 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | 0.46 | |||||
Interest Coverage | 35.63 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.95 | |||||
Beneish M-Score | -1.99 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.2 | |||||
3-Year EBITDA Growth Rate | 16.8 | |||||
3-Year EPS without NRI Growth Rate | 13.5 | |||||
3-Year Book Growth Rate | 10.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.48 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.09 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.58 | |||||
9-Day RSI | 74.58 | |||||
14-Day RSI | 76.8 | |||||
6-1 Month Momentum % | 21 | |||||
12-1 Month Momentum % | 11.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.86 | |||||
Quick Ratio | 1.86 | |||||
Cash Ratio | 0.9 | |||||
Days Inventory | 129.86 | |||||
Days Sales Outstanding | 64.96 | |||||
Days Payable | 85.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 4.53 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 28.81 | |||||
Operating Margin % | 14.42 | |||||
Net Margin % | 9.83 | |||||
FCF Margin % | 8.11 | |||||
ROE % | 17.32 | |||||
ROA % | 10.8 | |||||
ROIC % | 18.62 | |||||
ROC (Joel Greenblatt) % | 37.18 | |||||
ROCE % | 21.8 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 9.08 | |||||
Forward PE Ratio | 8.1 | |||||
PE Ratio without NRI | 8.95 | |||||
PEG Ratio | 1.42 | |||||
PS Ratio | 0.9 | |||||
PB Ratio | 1.47 | |||||
Price-to-Tangible-Book | 1.7 | |||||
Price-to-Free-Cash-Flow | 11.17 | |||||
Price-to-Operating-Cash-Flow | 5.93 | |||||
EV-to-EBIT | 5.36 | |||||
EV-to-EBITDA | 3.74 | |||||
EV-to-Revenue | 0.77 | |||||
EV-to-FCF | 9.46 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.5 | |||||
Price-to-Graham-Number | 0.82 | |||||
Price-to-Net-Current-Asset-Value | 2.35 | |||||
Earnings Yield (Greenblatt) % | 18.66 | |||||
FCF Yield % | 9.07 | |||||
Forward Rate of Return (Yacktman) % | 8.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Shedir Pharma Group SpA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 61.793 | ||
EPS (TTM) (€) | 0.535 | ||
Beta | 0.57 | ||
Volatility % | 30.48 | ||
14-Day RSI | 76.8 | ||
14-Day ATR (€) | 0.029294 | ||
20-Day SMA (€) | 4.853 | ||
12-1 Month Momentum % | 11.01 | ||
52-Week Range (€) | 3.34 - 4.88 | ||
Shares Outstanding (Mil) | 11.36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Shedir Pharma Group SpA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Shedir Pharma Group SpA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Shedir Pharma Group SpA Frequently Asked Questions
What is Shedir Pharma Group SpA(MIL:SHE)'s stock price today?
When is next earnings date of Shedir Pharma Group SpA(MIL:SHE)?
Does Shedir Pharma Group SpA(MIL:SHE) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |